Sign inJoin waitlistJoin the waitlist

Margaret Kasner

Director, Division of Hematologic Malignancies · SIDNEY KIMMEL MEDICAL COLLEGE AT THOMAS JEFFERSON UNIVERSITY

Credentials: · · · ·

History

Hospital of the University of Pennsylvania
2004–2007
Hospital of the University of Pennsylvania
2001–2004
The Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania
1997–2001

Research

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
New England Journal of Medicine · 2019 · 1,078 citations
High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction
Circulation · 2005 · 181 citations
The diabetes gene Pdx1 regulates the transcriptional network of pancreatic endocrine progenitor cells in mice
Journal of Clinical Investigation · 2009 · 141 citations

Lindsay Wilde
15 papers · 1 as a fellow
Joanne Filicko-O'Hara
14 papers
John Wagner
12 papers
MC
Matthew Carabasi
11 papers
Neil Palmisiano
11 papers · 7 as a resident
NF
Neal Flomenberg
10 papers
Gina Keiffer
8 papers · 2 as a fellow
Onder Alpdogan
8 papers
Chetan Jeurkar
6 papers · 4 as a fellow
Martin Carroll
6 papers
Selina Luger
6 papers
TK
Thomas Klumpp
6 papers

Grants

Translational Research in Cancer
National Cancer Institute · P30
Project lead · $625.4K · Thomas Jefferson University
1995–2024

Clinical trials

Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Principal investigator · Completed · Phase 1
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2018–2022
STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy
Principal investigator · Completed · Phase 1
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2017–2024
Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia
Principal investigator · Completed · Phase 2
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2015–2023
Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
Principal investigator · Completed · Phase 2
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2013–2024